Gilead Sciences Financial Health

Financial Health criteria checks 4/6

Gilead Sciences has a total shareholder equity of $20.9B and total debt of $25.2B, which brings its debt-to-equity ratio to 120.5%. Its total assets and total liabilities are $61.9B and $40.9B respectively. Gilead Sciences's EBIT is $10.2B making its interest coverage ratio 11. It has cash and short-term investments of $6.5B.

Key information

120.5%

Debt to equity ratio

US$25.24b

Debt

Interest coverage ratio11x
CashUS$6.52b
EquityUS$20.94b
Total liabilitiesUS$40.94b
Total assetsUS$61.88b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: GIS's short term assets ($13.5B) exceed its short term liabilities ($10.5B).

Long Term Liabilities: GIS's short term assets ($13.5B) do not cover its long term liabilities ($30.4B).


Debt to Equity History and Analysis

Debt Level: GIS's net debt to equity ratio (89.4%) is considered high.

Reducing Debt: GIS's debt to equity ratio has reduced from 140.7% to 120.5% over the past 5 years.

Debt Coverage: GIS's debt is well covered by operating cash flow (35.6%).

Interest Coverage: GIS's interest payments on its debt are well covered by EBIT (11x coverage).


Balance Sheet


Discover healthy companies